
HERO provides access to companies whose principal business have or are expected have significant exposure to the field of video games and esports. An algorithm screens company filings for keywords that match the index theme to identify and rank companies. Eligible securities meeting minimum market-cap and liquidity requirements must also generate at least 50% of its revenues from video games or esports activities to be selected for index inclusion. Securities are those in the emerging and developed countries. The fund also invests in ADRs and GDRs based on such securities, and is not limited…
Is HERO's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101.

Envestnet Asset Management Inc. raised its holdings in Global X Video Games and Esports ETF (NASDAQ: HERO) by 306.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 141,909 shares of the company's stock after purchasing an additional 106,976 shares during the

AARD DEADLINE NOTICE: Faruqi and Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026PR NewswireNEW YORK,

AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class ActionPR NewswireSAN FRANCISCO,